Our subgroup analysis for patients with different IPI and stages suggests that low SAMHD1 expression may benefit DLBCL patients with moderate to high risk (IPI 2–5) and more advanced stages (III-IV) for which about 60% of patients are diagnosed. This evidence concerns the gene SAMHD1 and diffuse large B-cell lymphoma.